Investigational drug · Phase 2
E6742
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Systemic Lupus Erythematosus.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "E6742"
First trial start
2026
Mar 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "E6742", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "E6742" as an intervention, largest first.
- A Study of E6742 in Participants With Systemic Lupus ErythematosusPivotal-lookingRecruiting
Eisai Co., Ltd.Eisai
NCT07515014 · 256 participants (planned) · Start Mar 31, 2026 · Primary completion Aug 5, 2028
Drug: E6742 · For: Systemic Lupus Erythematosus
Sites: Bengbu, China; Beijing, China; Chongqing, China · 63 sites in all
Eisai Inc.Eisai
NCT03082235 · 72 participants · Start Mar 3, 2017 · Primary completion Oct 11, 2017
Drug: E6742; Placebo · For: Healthy Participants
Sites: Glendale, California
Eisai Co., Ltd.Eisai
NCT05278663 · 26 participants · Start Apr 14, 2022 · Primary completion Sep 4, 2023
Drug: E6742 · For: Lupus Erythematosus, Systemic
Sites: Nagoya, Japan; Matsuyama, Japan; Kitakyushu, Japan · 12 sites in all
- A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult ParticipantsCompleted
Eisai Co., Ltd.Eisai
NCT04683185 · 24 participants · Start Dec 28, 2020 · Primary completion Jun 21, 2021
Drug: E6742; Placebo · For: Healthy Volunteers
Sites: Bunkyō-Ku, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.
Tanaka Y, Kumanogoh A, Atsumi T, et al. · RMD Open 2024
- A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration.
Tanaka Y, Tago F, Yamakawa N, et al. · Immunol Med 2024
- A novel Toll-like receptor 7/8-specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus.
Ishizaka ST, Hawkins L, Chen Q, et al. · Eur J Pharmacol 2023
- First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers.
Yamakawa N, Tago F, Nakai K, et al. · Clin Pharmacol Drug Dev 2023
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eisai.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.